MiNA: MiNA and BioMarin partner to speed development of RNAa therapies
The agreement will see MiNA receive an upfront payment and future royalties if BioMarin exercises options from the deal.
Read full article »
MiNA is an England-based biotechnology company that develops and commercializes saRNA therapeutics for the treatment of cancer and genetic diseases.
Read more